Carbonic Anhydrase Inhibition with Benzenesulfonamides and Tetrafluorobenzenesulfonamides Obtained via Click Chemistry.

A series of novel benzene- and 2,3,5,6-tetrafluorobenzenesulfonamide was synthesized by using a click chemistry approach starting from azido-substituted sulfonamides and alkynes, incorporating aryl, alkyl, cycloalkyl, and amino-/hydroxy-/halogenoalkyl moieties. The new compounds were medium potency inhibitors of the cytosolic carbonic anhydrase (CA, EC 4.2.1.1) isoforms I and II and low nanomolar/subnanomolar inhibitors of the tumor-associated hCA IX and XII isoforms. The X-ray crystal structure of two such sulfonamides in adduct with hCA II allowed us to understand the factors governing inhibitory power.

[1]  C. Supuran,et al.  A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. , 2014, Angewandte Chemie.

[2]  C. D. Boone,et al.  Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases. , 2013, Bioorganic & medicinal chemistry.

[3]  C. Supuran,et al.  5-Substituted-(1,2,3-triazol-4-yl)thiophene-2-sulfonamides strongly inhibit human carbonic anhydrases I, II, IX and XII: solution and X-ray crystallographic studies. , 2013, Bioorganic & medicinal chemistry.

[4]  C. Supuran,et al.  Thiol-ene click chemistry for the synthesis of highly effective glycosyl sulfonamide carbonic anhydrase inhibitors. , 2013, Chemical communications.

[5]  C. Supuran.  Structure-based drug discovery of carbonic anhydrase inhibitors , 2012, Journal of enzyme inhibition and medicinal chemistry.

[6]  F. Da Settimo,et al.  Tricyclic sulfonamides incorporating benzothiopyrano[4,3-c]pyrazole and pyridothiopyrano[4,3-c]pyrazole effectively inhibit α- and β-carbonic anhydrase: X-ray crystallography and solution investigations on 15 isoforms. , 2012, Journal of medicinal chemistry.

[7]  C. Supuran,et al.  Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? , 2012, Chemical reviews.

[8]  C. Supuran,et al.  Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of N-substituted benzenesulfonamides to human isoform II. , 2011, Chemical communications.

[9]  C. Supuran,et al.  Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. , 2011, Journal of medicinal chemistry.

[10]  C. Supuran,et al.  Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms. , 2011, Bioorganic & medicinal chemistry.

[11]  Vladimir Garaj,et al.  Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: Solution and X-ray crystallographic studies. , 2011, Bioorganic & medicinal chemistry.

[12]  C. Supuran,et al.  Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[13]  Brendan L Wilkinson,et al.  Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. , 2008, Journal of medicinal chemistry.

[14]  Claudiu T. Supuran,et al.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators , 2008, Nature Reviews Drug Discovery.

[15]  Brendan L Wilkinson,et al.  Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides. , 2007, Journal of medicinal chemistry.

[16]  Chi-Huey Wong,et al.  In situ click chemistry: enzyme-generated inhibitors of carbonic anhydrase II. , 2004, Angewandte Chemie.

[17]  C. Supuran,et al.  Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. , 2000, Journal of medicinal chemistry.